title: RMP exposure is lower in HIV-infected TB patients receiving intermittent than daily anti-tuberculosis treatment.
abstract: We compared the pharmacokinetics of rifampicin (RMP) during daily and intermittent (thrice weekly) anti-tuberculosis treatment in human immunodeficiency virus infected tuberculosis patients. Patients treated with a thrice-weekly regimen had significantly lower plasma peak concentration, area under the time concentration curve from 0 to 24 h and higher oral clearance of RMP than those treated with the daily regimen. The median values were respectively 3.7 and 6.4 μg/ml (P < 0.001), 20.7 and 29.4 μg/ml.h (P = 0.03) and 21.7 and 15.3 ml/min (P = 0.03).
authors.affiliation: National Institute for Research in Tuberculosis, Chennai, India.
authors.forename: A K
authors.initials: AK
authors.lastname: Hemanth Kumar
authors.affiliation: National Institute for Research in Tuberculosis, Chennai, India.
authors.forename: G
authors.initials: G
authors.lastname: Narendran
authors.affiliation: National Institute for Research in Tuberculosis, Chennai, India.
authors.forename: R S
authors.initials: RS
authors.lastname: Kumar
authors.affiliation: National Institute for Research in Tuberculosis, Chennai, India.
authors.forename: G
authors.initials: G
authors.lastname: Ramachandran
authors.affiliation: National Institute for Research in Tuberculosis, Chennai, India.
authors.forename: L
authors.initials: L
authors.lastname: Sekar
authors.affiliation: Government Hospital of Thoracic Medicine, Chennai, India.
authors.forename: K
authors.initials: K
authors.lastname: Raja
authors.affiliation: National Institute for Research in Tuberculosis, Chennai, India.
authors.forename: S
authors.initials: S
authors.lastname: Swaminathan
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage*; D018791:CD4 Lymphocyte Count; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007194:India; D008297:Male; D011446:Prospective Studies; D012293:Rifampin / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D012293:Rifampin